Zydus Lifesciences’ arm enters into strategic partnership with Bioeq AG

24 Dec 2025 Evaluate

Zydus Lifesciences’ wholly owned subsidiary -- Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq AG (Bioeq), a Swiss biopharmaceutical company, for the licensing, supply and commercialization of Bioeq’s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. 

This transaction marks an expansion of Zydus’ U.S. biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda (Pembrolizumab). Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO in the U.S. market.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


Zydus Lifesciences Share Price

917.45 -10.65 (-1.15%)
24-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1737.50
Dr. Reddys Lab 1266.35
Cipla 1496.35
Zydus Lifesciences 917.45
Lupin 2109.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×